TheratOcular Biotek, a clinical-stage biotechnology company, is exclusively focusing on development of user-friendly and cost-effective treatments for diseases and conditions of the eye. With its proprietary site-targeting drug delivery technology and patented ophthalmic-friendly formulations, TheratOcular is able to select a group of approved systemic drugs with proven mechanism of action and safety records in human to treat a variety of eye diseases as 505b2 candidates. Our product and business development strategy is to quickly advance the right drug candidates to proof-of-concept (POC) Phase II stage for out-licensing and collaboration partnership.